Questions, answered plainly.

PrecisionCardio Industry Alliance is a nonprofit, member-governed industry association for biotechnology and pharmaceutical companies working across cardiovascular medicine. Members work together on shared, disease-level challenges that can appropriately be addressed pre-competitively.

Different cardiovascular diseases require different science and different workups, but many of the barriers that keep patients from reaching a precise diagnosis and disease-specific care recur across the field. PrecisionCardio gives companies a structure to address those shared barriers collectively.

No. Genetics is one important part of precision cardiovascular medicine, but disease-specific understanding may also come from phenotype, imaging, biomarkers, molecular characterization and other disease-directed evaluation.

Professional societies represent clinicians; patient organizations serve patients and families. PrecisionCardio is an industry alliance. It does not replace those organizations and expects to work with them as strategic partners when their expertise is relevant to a member-selected initiative.

PrecisionCardio Industry Alliance, Inc. is a nonprofit industry association incorporated in Delaware. The Alliance is seeking recognition from the Internal Revenue Service as a tax-exempt business league under Section 501(c)(6).

Members determine the priorities. Illustrative work could include professional-society education partnerships, clinician education, practical recognition or diagnostic resources, shared gap analyses, academic collaborations and other disease-level initiatives.

Members surface recurring challenges they are seeing and determine through PrecisionCardio's governance process which ones warrant collective attention. The program of work is member-selected rather than predetermined by staff.

The priority comes first. Once members select a shared question, PrecisionCardio identifies the professional society, patient organization, academic group, clinical experts or other strategic partners best suited to help advance that work.

It means companies collaborate on questions that can appropriately be addressed at the disease or field level without coordinating how individual companies compete. Disease-level challenges may be shared; product-specific decisions remain with each company.

Product-specific development decisions, product and commercial strategy, pricing, contracting and other competitively sensitive matters remain outside PrecisionCardio. Single-company promotional programs or work designed for the exclusive benefit of one member are also outside the model.

Membership is intended for eligible biotechnology and pharmaceutical companies working in cardiovascular medicine. Professional societies, patient organizations, academics and clinicians participate as partners, advisors or collaborators rather than as industry members.

Founding membership is open through December 2026. Founding members help shape PrecisionCardio's initial priorities, governance and first program of work.

PrecisionCardio is governed by its members and Board of Directors. The founding Board is being formed with the founding membership, with detailed governance provisions set out in the Alliance's governing documents.